Details of the Drug

General Information of Drug (ID: DMOX3LB)

Drug Name
Fosphenytoin
Synonyms
Fosfenitoina; Fosphenytoine; Fosphenytoinum; HMPDP; Prodilantin; ACC-9653; Cerebyx (TN); Fosfenitoina [INN-Spanish]; Fosphenytoin (INN); Fosphenytoin [INN:BAN]; Fosphenytoine [INN-French]; Fosphenytoinum [INN-Latin]; Prodilantin (TN); (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate; (3-Phosphoryloxymethyl)phenytoin; 3-(hydroxymethyl)phenytoin disodium phosphate; 3-(hydroxymethyl)phenytoin phosphate ester
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1]
Therapeutic Class
Anticonvulsants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 362.27
Topological Polar Surface Area (xlogp) 0.6
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.5 mL/min/kg [2]
Elimination
There is little unchanged phenytoin (1%C5% of the administered dose), and essentially no fosphenytoin recovered in urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 - 28.9 hours [3]
Metabolism
The drug is metabolized via phosphatases [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.05% [2]
Vd
The volume of distribution (Vd) of drug is 4.3-10.8 L [3]
Chemical Identifiers
Formula
C16H15N2O6P
IUPAC Name
(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl dihydrogen phosphate
Canonical SMILES
C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3
InChI
InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)
InChIKey
XWLUWCNOOVRFPX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
56339
ChEBI ID
CHEBI:5165
CAS Number
93390-81-9
DrugBank ID
DB01320
TTD ID
D0J5YC
VARIDT ID
DR00637
INTEDE ID
DR0751

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A) TTZOVE0 SCN5A_HUMAN Blocker [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fosphenytoin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Methsuximide DM6L5VO Moderate Increased metabolism of Fosphenytoin caused by Methsuximide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [38]
Stiripentol DMMSDOY Major Increased metabolism of Fosphenytoin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [39]
Eslicarbazepine DMZREFQ Moderate Decreased metabolism of Fosphenytoin caused by Eslicarbazepine mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [40]
Coadministration of a Drug Treating the Disease Different from Fosphenytoin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [41]
Ivosidenib DM8S6T7 Major Increased metabolism of Fosphenytoin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [42]
Midostaurin DMI6E0R Major Increased metabolism of Fosphenytoin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [43]
Gilteritinib DMWQ4MZ Major Increased metabolism of Fosphenytoin caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [44]
Emapalumab DMZG5WL Moderate Altered metabolism of Fosphenytoin due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [41]
Siltuximab DMGEATB Moderate Altered metabolism of Fosphenytoin due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [41]
Ivabradine DM0L594 Major Increased metabolism of Fosphenytoin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [41]
Dronedarone DMA8FS5 Moderate Increased metabolism of Fosphenytoin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [45]
Bedaquiline DM3906J Major Increased metabolism of Fosphenytoin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [41]
Roflumilast DMPGHY8 Moderate Increased metabolism of Fosphenytoin caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [46]
Troleandomycin DMUZNIG Moderate Increased metabolism of Fosphenytoin caused by Troleandomycin mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Cariprazine DMJYDVK Moderate Increased metabolism of Fosphenytoin caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [48]
Erdafitinib DMI782S Major Increased metabolism of Fosphenytoin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [49]
Pexidartinib DMS2J0Z Major Decreased metabolism of Fosphenytoin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [50]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Fosphenytoin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
HKI-272 DM6QOVN Major Increased metabolism of Fosphenytoin caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
LY2835219 DM93VBZ Major Increased metabolism of Fosphenytoin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Fosphenytoin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Palbociclib DMD7L94 Major Increased metabolism of Fosphenytoin caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Alpelisib DMEXMYK Major Increased metabolism of Fosphenytoin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Fosphenytoin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Fosphenytoin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [56]
Macitentan DMP79A1 Major Increased metabolism of Fosphenytoin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [57]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Fosphenytoin caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [58]
PF-04449913 DMSB068 Major Increased metabolism of Fosphenytoin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [59]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Fosphenytoin caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [60]
Regorafenib DMHSY1I Moderate Increased metabolism of Fosphenytoin caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [61]
Intedanib DMSTA36 Major Increased metabolism of Fosphenytoin caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [62]
Drospirenone DM1A9W3 Major Increased metabolism of Fosphenytoin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [54]
Levonorgestrel DM1DP7T Major Increased metabolism of Fosphenytoin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [54]
Ulipristal DMBNI20 Moderate Increased metabolism of Fosphenytoin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [41]
Mestranol DMG3F94 Major Increased metabolism of Fosphenytoin caused by Mestranol mediated induction of CYP450 enzyme. Contraceptive management [QA21] [63]
Atracurium DM42HXN Moderate Increased metabolism of Fosphenytoin caused by Atracurium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [64]
Pancuronium DMB0VY8 Moderate Increased metabolism of Fosphenytoin caused by Pancuronium mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [64]
Osilodrostat DMIJC9X Major Increased metabolism of Fosphenytoin caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [41]
Ivacaftor DMZC1HS Major Increased metabolism of Fosphenytoin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [52]
MK-8228 DMOB58Q Moderate Increased metabolism of Fosphenytoin caused by MK-8228 mediated induction of UGT. Cytomegaloviral disease [1D82] [52]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Fosphenytoin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [65]
Vilazodone DM4LECQ Moderate Increased metabolism of Fosphenytoin caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Moderate Increased metabolism of Fosphenytoin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [67]
OPC-34712 DMHG57U Moderate Increased metabolism of Fosphenytoin caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [68]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Fosphenytoin and Esketamine. Depression [6A70-6A7Z] [52]
Empagliflozin DMRF9YK Moderate Increased metabolism of Fosphenytoin caused by Empagliflozin mediated induction of UGT. Diabetes mellitus [5A10] [52]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Fosphenytoin caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [52]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Fosphenytoin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [69]
Ospemifene DMC4GEI Moderate Increased metabolism of Fosphenytoin caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [70]
Ingrezza DMVPLNC Major Increased metabolism of Fosphenytoin caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [71]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Fosphenytoin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [63]
Cannabidiol DM0659E Moderate Increased metabolism of Fosphenytoin caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [41]
Bay 80-6946 DMLOS5R Major Increased metabolism of Fosphenytoin caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [72]
Tazemetostat DMWP1BH Major Increased metabolism of Fosphenytoin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [73]
Mirabegron DMS1GYT Minor Increased metabolism of Fosphenytoin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [74]
Ripretinib DM958QB Major Increased metabolism of Fosphenytoin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [75]
Avapritinib DMK2GZX Major Increased metabolism of Fosphenytoin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [41]
Boceprevir DMBSHMF Major Increased metabolism of Fosphenytoin caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [76]
PSI-7977 DMLSUWZ Major Accelerated clearance of Fosphenytoin due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [41]
Simeprevir DMLUA9D Major Increased metabolism of Fosphenytoin caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [77]
Telaprevir DMMRV29 Major Increased metabolism of Fosphenytoin caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [78]
ABT-267 DMNQ869 Major Increased metabolism of Fosphenytoin caused by ABT-267 mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Daclatasvir DMSFK9V Major Increased metabolism of Fosphenytoin caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [41]
Pretomanid DMDYA31 Major Increased metabolism of Fosphenytoin caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [79]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Fosphenytoin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [80]
MK-1439 DM215WE Major Increased metabolism of Fosphenytoin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Fostemsavir DM50ILT Major Increased metabolism of Fosphenytoin caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [82]
Cobicistat DM6L4H2 Major Increased metabolism of Fosphenytoin caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Dolutegravir DMCZGRE Major Increased metabolism of Fosphenytoin caused by Dolutegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [52]
Elvitegravir DMG9B1U Major Increased metabolism of Fosphenytoin caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Etravirine DMGV8QU Major Increased metabolism of Fosphenytoin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [83]
Lopinavir DMITQS0 Major Increased metabolism of Fosphenytoin caused by Lopinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [52]
Rilpivirine DMJ0QOW Major Increased metabolism of Fosphenytoin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [84]
Maraviroc DMTL94F Major Increased metabolism of Fosphenytoin caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Fosphenytoin and Mipomersen. Hyper-lipoproteinaemia [5C80] [86]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Fosphenytoin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [65]
Levamlodipine DM92S6N Major Increased metabolism of Fosphenytoin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [87]
Tolvaptan DMIWFRL Major Increased metabolism of Fosphenytoin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [41]
Pirfenidone DM6VZFQ Moderate Increased metabolism of Fosphenytoin caused by Pirfenidone mediated induction of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [41]
Lesinurad DMUR64T Moderate Increased metabolism of Fosphenytoin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [88]
TP-434 DM5A31S Major Increased metabolism of Fosphenytoin caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [89]
Suvorexant DM0E6S3 Major Increased metabolism of Fosphenytoin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [90]
Amobarbital DM0GQ8N Moderate Increased metabolism of Fosphenytoin caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [91]
Tasimelteon DMLOQ1V Major Increased metabolism of Fosphenytoin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [92]
ITI-007 DMUQ1DO Major Increased metabolism of Fosphenytoin caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [93]
Quazepam DMY4D87 Moderate Increased metabolism of Fosphenytoin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [94]
Remimazolam DMLVSYX Moderate Increased metabolism of Fosphenytoin caused by Remimazolam mediated induction of CYP450 enzyme. Labour/delivery anaesthesia complication [JB0C] [94]
Naloxegol DML0B41 Major Increased metabolism of Fosphenytoin caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [41]
Pemigatinib DM819JF Major Increased metabolism of Fosphenytoin caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [41]
Crizotinib DM4F29C Major Increased metabolism of Fosphenytoin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [52]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Fosphenytoin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [95]
Osimertinib DMRJLAT Major Increased metabolism of Fosphenytoin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [52]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by BIBW 2992. Lung cancer [2C25] [96]
Pralsetinib DMWU0I2 Major Increased metabolism of Fosphenytoin caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [97]
Capmatinib DMYCXKL Major Increased metabolism of Fosphenytoin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [98]
Selpercatinib DMZR15V Major Increased metabolism of Fosphenytoin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [41]
Artemether DM48QOT Major Increased metabolism of Fosphenytoin caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [52]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Fosphenytoin when combined with Hydroxychloroquine. Malaria [1F40-1F45] [52]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Fosphenytoin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [99]
Idelalisib DM602WT Major Accelerated clearance of Fosphenytoin due to the transporter induction by Idelalisib. Mature B-cell leukaemia [2A82] [100]
GDC-0199 DMH0QKA Major Increased metabolism of Fosphenytoin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [101]
IPI-145 DMWA24P Major Increased metabolism of Fosphenytoin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [102]
Acalabrutinib DM7GCVW Major Increased metabolism of Fosphenytoin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [103]
Ibrutinib DMHZCPO Major Increased metabolism of Fosphenytoin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [41]
Ponatinib DMYGJQO Moderate Increased metabolism of Fosphenytoin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [52]
Arry-162 DM1P6FR Moderate Increased metabolism of Fosphenytoin caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [52]
Vemurafenib DM62UG5 Major Increased metabolism of Fosphenytoin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Selumetinib DMC7W6R Major Increased metabolism of Fosphenytoin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [104]
LGX818 DMNQXV8 Major Increased metabolism of Fosphenytoin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [105]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Fosphenytoin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [52]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Fosphenytoin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [106]
Ubrogepant DM749I3 Major Increased metabolism of Fosphenytoin caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [107]
Rimegepant DMHOAUG Major Increased metabolism of Fosphenytoin caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [108]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Fosphenytoin and Lasmiditan. Migraine [8A80] [109]
Flibanserin DM70DTN Major Increased metabolism of Fosphenytoin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [110]
Panobinostat DM58WKG Major Increased metabolism of Fosphenytoin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [111]
Siponimod DM2R86O Major Increased metabolism of Fosphenytoin caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [52]
Deflazacort DMV0RNS Major Increased metabolism of Fosphenytoin caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [41]
Romidepsin DMT5GNL Moderate Increased metabolism of Fosphenytoin caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [112]
Fedratinib DM4ZBK6 Major Increased metabolism of Fosphenytoin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [41]
Nilotinib DM7HXWT Major Increased metabolism of Fosphenytoin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [113]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Fosphenytoin caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [114]
Vorapaxar DMA16BR Major Increased metabolism of Fosphenytoin caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [115]
Rolapitant DM8XP26 Major Increased metabolism of Fosphenytoin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [41]
E-2007 DMJDYNQ Moderate Increased metabolism of Fosphenytoin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [41]
Entrectinib DMMPTLH Major Increased metabolism of Fosphenytoin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [116]
S-297995 DM26IH8 Major Increased metabolism of Fosphenytoin caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [117]
Olaparib DM8QB1D Major Increased metabolism of Fosphenytoin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [52]
Rucaparib DM9PVX8 Moderate Increased metabolism of Fosphenytoin caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [118]
MK-4827 DMLYGH4 Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by MK-4827. Ovarian cancer [2C73] [119]
Istradefylline DM20VSK Major Increased metabolism of Fosphenytoin caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [120]
Pimavanserin DMR7IVC Moderate Increased metabolism of Fosphenytoin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [121]
Macimorelin DMQYJIR Moderate Increased metabolism of Fosphenytoin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [122]
Lonafarnib DMGM2Z6 Major Increased metabolism of Fosphenytoin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [123]
Enzalutamide DMGL19D Moderate Increased metabolism of Fosphenytoin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [124]
Relugolix DMK7IWL Major Increased metabolism of Fosphenytoin caused by Relugolix mediated induction of CYP450 enzyme. Prostate cancer [2C82] [125]
Darolutamide DMV7YFT Major Increased metabolism of Fosphenytoin caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [126]
Silodosin DMJSBT6 Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [52]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Fosphenytoin due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [41]
Apremilast DMTWS9E Major Increased metabolism of Fosphenytoin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [127]
Ixekizumab DMXW92T Moderate Altered metabolism of Fosphenytoin due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [41]
Riociguat DMXBLMP Moderate Increased metabolism of Fosphenytoin caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [128]
Everolimus DM8X2EH Major Increased metabolism of Fosphenytoin caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [65]
Axitinib DMGVH6N Major Increased metabolism of Fosphenytoin caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [129]
Temsirolimus DMS104F Major Increased metabolism of Fosphenytoin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [52]
Upadacitinib DM32B5U Major Increased metabolism of Fosphenytoin caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [130]
Tocilizumab DM7J6OR Moderate Altered metabolism of Fosphenytoin due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [41]
Canakinumab DM8HLO5 Moderate Altered metabolism of Fosphenytoin due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [41]
Tofacitinib DMBS370 Major Increased metabolism of Fosphenytoin caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [52]
Rilonacept DMGLUQS Moderate Altered metabolism of Fosphenytoin due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [41]
Golimumab DMHZV7X Moderate Altered metabolism of Fosphenytoin due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [41]
Avanafil DM75CXN Moderate Increased metabolism of Fosphenytoin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [131]
Voxelotor DMCS6M5 Major Increased metabolism of Fosphenytoin caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [132]
LDE225 DMM9F25 Major Increased metabolism of Fosphenytoin caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [133]
Larotrectinib DM26CQR Major Accelerated clearance of Fosphenytoin due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [52]
Trabectedin DMG3Y89 Major Increased metabolism of Fosphenytoin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [41]
Armodafinil DMGB035 Moderate Decreased metabolism of Fosphenytoin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [52]
LEE011 DMMX75K Major Increased metabolism of Fosphenytoin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [134]
Vandetanib DMRICNP Moderate Increased metabolism of Fosphenytoin caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [135]
Pitolisant DM8RFNJ Major Increased metabolism of Fosphenytoin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [41]
Pomalidomide DMTGBAX Moderate Increased metabolism of Fosphenytoin caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [136]
Fostamatinib DM6AUHV Major Increased metabolism of Fosphenytoin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [137]
As-1670542 DMV05SW Major Increased metabolism of Fosphenytoin caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [138]
Apixaban DM89JLN Major Increased metabolism of Fosphenytoin caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [41]
Brilinta DMBR01X Major Increased metabolism of Fosphenytoin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [139]
Cabozantinib DMIYDT4 Major Increased metabolism of Fosphenytoin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [140]
Pipecuronium DM5F84A Moderate Increased metabolism of Fosphenytoin caused by Pipecuronium mediated induction of CYP450 enzyme. Tonus and reflex abnormality [MB47] [64]
Canagliflozin DMFRM1I Moderate Increased metabolism of Fosphenytoin caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [52]
Linagliptin DMWFJTR Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by Linagliptin. Type 2 diabetes mellitus [5A11] [141]
Elagolix DMB2C0E Moderate Increased metabolism of Fosphenytoin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [142]
Betrixaban DM2C4RF Moderate Accelerated clearance of Fosphenytoin due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [143]
⏷ Show the Full List of 168 DDI Information of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA Approved Drug Products: SESQUIENT (fosphenytoin) injection
4 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
5 Basic review of the cytochrome p450 system. J Adv Pract Oncol. 2013 Jul;4(4):263-8.
6 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
7 CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity. J Clin Pharmacol. 2009 Dec;49(12):1483-7.
8 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
9 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
10 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
11 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
12 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
13 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
14 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
15 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
16 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
17 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
18 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
19 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
20 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
21 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
22 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
23 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
24 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
25 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
26 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
27 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
28 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
29 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
30 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
31 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
32 Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
33 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
34 Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
35 Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
36 From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.
37 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
38 Browne TR, Feldman RG, Buchanan RA, et al. "Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions." Neurology 33 (1983): 414-8. [PMID: 6403891]
39 Cazali N, Tran A, Treluyer JM, et al. "Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human." Br J Clin Pharmacol 56 (2003): 526-36. [PMID: 14651727]
40 Bialer M, Soares-da-Silva P "Pharmacokinetics and drug interactions of eslicarbazepine acetate." Epilepsia 53 (2012): 935-46. [PMID: 22612290]
41 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
42 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
43 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
44 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
45 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
46 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
47 Bachmann K, Schwartz JI, Forney RB Jr, Jauregui L "Single dose phenytoin clearance during erythromycin treatment." Res Commun Chem Pathol Pharmacol 46 (1984): 207-17. [PMID: 6515115]
48 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
49 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
50 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
51 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
52 Cerner Multum, Inc. "Australian Product Information.".
53 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
54 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
55 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
56 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
57 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
58 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
59 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
61 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
62 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
63 Back DJ, Grimmer SF, Orme ML, Proudlove D, Mann RD, Breckenridge AM "Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics." Br J Clin Pharmacol 25 (1988): 527-32. [PMID: 3408633]
64 Liberman BA, Norman P, Hardy BG "Pancuronium-phenytoin interaction: a case of decreased duration of neuromuscular blockade." Int J Clin Pharmacol Ther Toxicol 26 (1988): 371-4. [PMID: 3220609]
65 Canadian Pharmacists Association.
66 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
67 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
68 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
69 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
70 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
71 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
72 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
73 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
74 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
75 Product Information. Qinlock (ripretinib). Deciphera Pharmaceuticals, Waltham, MA.
76 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
77 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
78 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
79 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
80 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
81 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
82 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
83 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
84 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
85 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
86 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
87 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
88 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
89 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
90 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
91 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
92 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
93 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
94 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
95 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
96 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
97 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
98 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
99 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
100 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
101 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
102 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
103 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
104 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
105 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
106 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
107 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
108 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
109 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
110 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
111 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
112 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
113 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
114 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
115 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
116 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
117 Product Information. Symproic (naldemedine). Shionogi USA Inc, Florham Park, NJ.
118 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
119 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
120 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
121 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
122 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
123 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
124 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
125 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
126 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
127 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
128 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
129 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
130 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
131 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
132 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
133 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
134 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
135 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
136 Product Information. Pomalyst (pomalidomide). QLT Phototherapeutics Inc, Vancouver, AZ.
137 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
138 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
139 Product Information. Brilinta (ticagrelor). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
140 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
141 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
142 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
143 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]